Ixekizumab

Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights

Retrieved on: 
Tuesday, October 3, 2023

This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.

Key Points: 
  • This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.
  • Spherix Global Insights recently published its seventh annual Patient Chart Dynamix™: Triggers and Drivers in Psoriatic Arthritis, (previously RealWorld Dynamix: Switching in Psoriatic Arthritis).
  • Patients receiving TNFs are also provided an ample period of treatment in the first-line setting before considering a switch to an alternative therapy.
  • Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.

Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease

Retrieved on: 
Tuesday, August 15, 2023

The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.

Key Points: 
  • The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.
  • A patent application has been filed covering the antibody and its therapeutic use.
  • The researchers are seeking commercial partners willing to conduct a large-scale clinical evaluation of Ab-IPL-IL17™ in patients with immune-mediated inflammatory diseases (IMIDs).
  • For commercial enquiries contact Dr Veemal Bhowruth at University of Birmingham Enterprise.

Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease

Retrieved on: 
Tuesday, August 15, 2023

The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.

Key Points: 
  • The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.
  • A patent application has been filed covering the antibody and its therapeutic use.
  • The researchers are seeking commercial partners willing to conduct a large-scale clinical evaluation of Ab-IPL-IL17™ in patients with immune-mediated inflammatory diseases (IMIDs).
  • For commercial enquiries contact Dr Veemal Bhowruth at University of Birmingham Enterprise.

Global Psoriatic Arthritis Treatment Market Report 2023: Recent Development of Interleukin-17 Inhibitors Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 18, 2023

It is a heterogeneous disease and is categorized into 5 subtypes, namely, symmetric psoriatic arthritis, asymmetric psoriatic arthritis, distal psoriatic arthritis, spondylitis, and arthritis mutilans.

Key Points: 
  • It is a heterogeneous disease and is categorized into 5 subtypes, namely, symmetric psoriatic arthritis, asymmetric psoriatic arthritis, distal psoriatic arthritis, spondylitis, and arthritis mutilans.
  • The factors driving the psoriatic arthritis treatment market are rising public health awareness regarding skin diseases, early disease diagnosis, and the recent development of interleukin-17 inhibitors.
  • Currently, the drugs prescribed for psoriatic arthritis are based on the severity of the disease such as mild, moderate, or severe psoriatic arthritis.
  • The development of Interleukin-17 inhibitors such as secukinumab, ixekizumab, and brodalumab have better drug safety and efficacy for the treatment of psoriatic arthritis.

Eli Lilly's Olumiant is Filling a Critical Gap for Severe Alopecia Areata Patients, According to Spherix Global Insights

Retrieved on: 
Thursday, November 17, 2022

EXTON, Pa., Nov. 17, 2022 /PRNewswire/ -- On June 13, 2022, Eli Lilly announced the FDA approval of Olumiant for severe alopecia areata (AA), making it the first systemic therapy available in the US to treat the disease. In July 2022, Spherix began tracking the launch of Olumiant as part of the Launch Dynamix™ series, in which approximately 75 US dermatologists provide perspectives on their use and perceptions of Olumiant in AA on a monthly basis.

Key Points: 
  • Despite this growth, the number of patients actually prescribed Olumiant suggests dermatologists are very much still in trial mode.
  • Dermatologists are often prescribing Olumiant to patients with severe disease, or 50-99% scalp hair loss, and often after multiple alternative treatment attempts.
  • Despite the vocalized desire amongst sampled dermatologists for increased education from the manufacturer, Olumiant is clearly filling a once-felt void of treatment.
  • To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn and Twitter .

Global Axial Spondyloarthritis Market Analysis and Forecasts, 2022-2032: Focus on Commercialized Therapies, Potential Pipeline Products, Indication, and Country - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 15, 2022

The "Axial Spondyloarthritis Market - A Global and Country Analysis: Focus on Commercialized Therapies, Potential Pipeline Products, Indication, and Country - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Axial Spondyloarthritis Market - A Global and Country Analysis: Focus on Commercialized Therapies, Potential Pipeline Products, Indication, and Country - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • The companies operating in the global axial spondyloarthritis market are now focusing more on biologics and personalized therapy to enhance therapeutics and improve patient outcomes.
  • Increasing investments in the research and development of drug manufacturing is one of the major opportunities in the global axial spondyloarthritis market.
  • The ankylosing spondyloarthritis segment dominated the global axial spondyloarthritis market in 2021 due to a greater number of product approvals in seven major countries compared to non-radiographic axial spondyloarthritis.

Novartis' Cosentyx and Eli Lilly's Taltz Remain Leaders in US and EU5 Psoriatic Arthritis Switching Market, but Janssen's Tremfya and AbbVie's Skyrizi Are Picking Up Steam, Spherix Reports

Retrieved on: 
Tuesday, June 14, 2022

EXTON, Pa., June 14, 2022 /PRNewswire/ -- Spherix Global Insights, a leading market intelligence firm specializing in immunology-based research and insights, recently published several large-scale patient audits focused on psoriatic arthritis (PsA) patients recently switched from one advanced systemic agent to another. Rheumatologists and dermatologists in the United States report that just under one-in-three of their biologic/small molecule-treated PsA patients are switched from one brand to another each year, while those from the EU5 report the same for approximately one-in-four patients.

Key Points: 
  • As such, nearly equal parts of patients were switched between TNFs as were switched from a TNF to an AMOA.
  • Conversely, those treated by a dermatologist (n=510 patients) are substantially less likely to be treated with back-to-back TNFs.
  • However, dermatologists are prescribing Tremfya and Skyrizi to nearly double the amount of later-line PsA patients than their rheumatology counterparts.
  • Counter to brand patterns revealed by the rheumatology audit, US dermatologists favor Taltz over Cosentyx, while Skyrizi and Tremfya switches are neck and neck.

Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study

Retrieved on: 
Wednesday, June 2, 2021

"We are excited to present a range of new data at EULAR that demonstrate treatment with Taltz provides consistent, long-term efficacy on common signs and symptoms over time in axial spondyloarthritis."

Key Points: 
  • "We are excited to present a range of new data at EULAR that demonstrate treatment with Taltz provides consistent, long-term efficacy on common signs and symptoms over time in axial spondyloarthritis."
  • In COAST-Y, Taltz showed consistent and sustained long-term improvements in signs and symptoms, functionality and quality of life in patients with r- and nr-axSpA.
  • Additional results from the Phase 3 COAST-Y study were also recently published in the Annals of the Rheumatic Diseases.
  • Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis.

UNION therapeutics A/S receives FDA approval for IND of oral next generation PDE4-inhibitor (orismilast) for investigation in plaque psoriasis

Retrieved on: 
Thursday, January 7, 2021

With the IND approval, UNION is granted permission to advance oral orismilast into Phase 2b trials in humans with moderate to severe plaque psoriasis to evaluate the safety and efficacy of orismilast.

Key Points: 
  • With the IND approval, UNION is granted permission to advance oral orismilast into Phase 2b trials in humans with moderate to severe plaque psoriasis to evaluate the safety and efficacy of orismilast.
  • Currently, oral treatment options for plaque psoriasis are limited, and many patients with moderate-to-severe psoriasis are receiving systemic injectable therapies.
  • Oral orismilast would therefore offer an efficacious and patient-friendly treatment," says UNION co-founder Professor Morten Sommer.
  • We confidently believe in the benefits of oral orismilast, and the IND approval marks a significant milestone in our clinical development."

UNION therapeutics A/S receives FDA approval for IND of oral next generation PDE4-inhibitor (orismilast) for investigation in plaque psoriasis

Retrieved on: 
Thursday, January 7, 2021

With the IND approval, UNION is granted permission to advance oral orismilast into Phase 2b trials in humans with moderate to severe plaque psoriasis to evaluate the safety and efficacy of orismilast.

Key Points: 
  • With the IND approval, UNION is granted permission to advance oral orismilast into Phase 2b trials in humans with moderate to severe plaque psoriasis to evaluate the safety and efficacy of orismilast.
  • Currently, oral treatment options for plaque psoriasis are limited, and many patients with moderate-to-severe psoriasis are receiving systemic injectable therapies.
  • Oral orismilast would therefore offer an efficacious and patient-friendly treatment," says UNION co-founder Professor Morten Sommer.
  • We confidently believe in the benefits of oral orismilast, and the IND approval marks a significant milestone in our clinical development."